Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.83 |
| ▸ | HTR2C | P28335 | 19/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.83 |
| ▸ | DRD2 | P14416 | 10/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210193 | 0.91 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL7256339 | 0.90 | HTR2A (0.69) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6589393 | 0.87 | HTR2A (0.87) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6588137 | 0.86 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6586485 | 0.84 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6588947 | 0.83 | HTR2A (0.77) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6586349 | 0.83 | HTR2A (0.75) | HTR2AHTR2CKCNH2DRD2 | |
| Methyl Benzoate SCHEMBL7256335 | 0.82 | HTR2A (0.59) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6586480 | 0.82 | HTR2A (0.78) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6586256 | 0.81 | HTR2A (0.70) | HTR2AHTR2CKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777430-B2 | A DERIVATIVES WITH ATTACHED TO AN N-ARYLALKYL-SUBSTITUTED AZETIDINE, PYRROLIDINE OR PIPERIDINE RING; A SERATONIN RECEPTOR ANTAGONISTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER SCHIZOPHRENIA, DEPRESSION | MERCK SHARP & DOHME LTD. | 2004-08-17 | — | — | US | disclosed |
| EP-1147084-B1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | disclosed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.